SHANNON MARTIN: Open Payments
NPI 1417322926 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,147 in 49 payments from 16 companies in 2025. Trend: 2023 $776 · 2024 $962 · 2025 $1,147
Food & beverage: $1,147
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $179 |
| Novo Nordisk Inc | 8 | $178 |
| Indivior Inc. | 5 | $142 |
| Alkermes, Inc. | 4 | $98 |
| ABBVIE INC. | 5 | $96 |
| Teva Pharmaceuticals USA, Inc. | 3 | $72 |
| Collegium Pharmaceutical, Inc. | 3 | $56 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Orexo US, Inc. | 3 | $47 |
| Boston Scientific Corporation | 2 | $45 |
Products named: REXULTI, Wegovy, SUBLOCADE, VIVITROL, AUSTEDO XR, VRAYLAR, Jornay PM, Auvelity.
Industry payments across MD — which companies pay providers there.
